Aaron Ellenbogen

4.3k total citations
40 papers, 1.1k citations indexed

About

Aaron Ellenbogen is a scholar working on Neurology, Cellular and Molecular Neuroscience and Cognitive Neuroscience. According to data from OpenAlex, Aaron Ellenbogen has authored 40 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Neurology, 9 papers in Cellular and Molecular Neuroscience and 9 papers in Cognitive Neuroscience. Recurrent topics in Aaron Ellenbogen's work include Parkinson's Disease Mechanisms and Treatments (33 papers), Neurological disorders and treatments (29 papers) and Restless Legs Syndrome Research (8 papers). Aaron Ellenbogen is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (33 papers), Neurological disorders and treatments (29 papers) and Restless Legs Syndrome Research (8 papers). Aaron Ellenbogen collaborates with scholars based in United States, Italy and Austria. Aaron Ellenbogen's co-authors include Philip M. Becker, Robert A. Hauser, Clete A. Kushida, Ronald W. Barrett, Ira Goodman, Beth Safirstein, Stuart Isaacson, Fabrizio Stocchi, Suneel Gupta and Ann Hsu and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and Archives of Physical Medicine and Rehabilitation.

In The Last Decade

Aaron Ellenbogen

38 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aaron Ellenbogen United States 16 891 342 270 255 152 40 1.1k
Adjmal Nahimi Denmark 15 623 0.7× 316 0.9× 173 0.6× 106 0.4× 101 0.7× 23 866
Tiffany Young United States 8 610 0.7× 113 0.3× 389 1.4× 311 1.2× 239 1.6× 12 1.0k
Karen Frei United States 18 587 0.7× 220 0.6× 92 0.3× 100 0.4× 352 2.3× 38 1.3k
Oren Cohen Israel 18 563 0.6× 336 1.0× 120 0.4× 51 0.2× 134 0.9× 43 1.0k
Toni L. Pitcher New Zealand 17 780 0.9× 156 0.5× 241 0.9× 46 0.2× 168 1.1× 31 1.1k
Michail E. Kalaitzakis United Kingdom 12 646 0.7× 241 0.7× 128 0.5× 65 0.3× 299 2.0× 13 947
Shunnan Ge China 17 280 0.3× 268 0.8× 98 0.4× 74 0.3× 123 0.8× 55 805
Sara Pietracupa Italy 18 596 0.7× 168 0.5× 132 0.5× 46 0.2× 82 0.5× 32 805
T. Shibazaki Japan 17 454 0.5× 379 1.1× 161 0.6× 134 0.5× 45 0.3× 43 924
Silvia Eshuis Netherlands 6 613 0.7× 281 0.8× 111 0.4× 50 0.2× 136 0.9× 8 907

Countries citing papers authored by Aaron Ellenbogen

Since Specialization
Citations

This map shows the geographic impact of Aaron Ellenbogen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron Ellenbogen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron Ellenbogen more than expected).

Fields of papers citing papers by Aaron Ellenbogen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aaron Ellenbogen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron Ellenbogen. The network helps show where Aaron Ellenbogen may publish in the future.

Co-authorship network of co-authors of Aaron Ellenbogen

This figure shows the co-authorship network connecting the top 25 collaborators of Aaron Ellenbogen. A scholar is included among the top collaborators of Aaron Ellenbogen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aaron Ellenbogen. Aaron Ellenbogen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McAllister, Peter, Atul T. Patel, Aaron Ellenbogen, et al.. (2025). Long‐Term Safety and Efficacy of Repeat Treatments with DaxibotulinumtoxinA in Cervical Dystonia: Results from the ASPEN ‐Open‐Label Study. Movement Disorders Clinical Practice. 12(11). 1764–1773.
2.
3.
Werner, Milton H., C. Warren Olanow, Andrew McGarry, et al.. (2024). A Phase I, Randomized, SAD, MAD, and PK Study of Risvodetinib in Older Adults and Parkinson’s Disease. Journal of Parkinson s Disease. 14(2). 325–334. 4 indexed citations
4.
Hauser, Robert A., Alberto J. Espay, Aaron Ellenbogen, et al.. (2023). IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease. JAMA Neurology. 80(10). 1062–1062. 20 indexed citations
5.
Olanow, C. Warren, Alberto J. Espay, Fabrizio Stocchi, et al.. (2020). Continuous Subcutaneous Levodopa Delivery for Parkinson’s Disease: A Randomized Study. Journal of Parkinson s Disease. 11(1). 177–186. 35 indexed citations
6.
Safirstein, Beth, et al.. (2020). Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. Clinical Therapeutics. 42(6). 1034–1046. 15 indexed citations
7.
Ellenbogen, Aaron, Fabrizio Stocchi, Alberto J. Espay, et al.. (2020). Impact of Subcutaneous Levodopa Infusion with ND0612 on Patient Reported Outcomes (4506). Neurology. 94(15_supplement). 4 indexed citations
8.
Bryś, Mirosław, Laura Fanning, Serena Hung, et al.. (2019). Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054. Movement Disorders. 34(8). 1154–1163. 139 indexed citations
9.
Hauser, Robert A., Aaron Ellenbogen, Sarita Khanna, Suneel Gupta, & Nishit B. Modi. (2018). Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease. Neuropsychiatric Disease and Treatment. Volume 14. 839–845. 13 indexed citations
10.
Bryś, Mirosław, Aaron Ellenbogen, Laura Fanning, et al.. (2018). Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Anti-Alpha-Synuclein Antibody BIIB054 in Patients with Parkinson’s Disease (S26.001). Neurology. 90(15_supplement). 17 indexed citations
11.
Ellenbogen, Aaron, Robert A. Hauser, Stuart Isaacson, et al.. (2018). Inhaled Levodopa Administered With Oral Carbidopa/Levodopa for Early Morning OFF Symptoms in Patients With Parkinson’s Disease: Safety Assessment (S26.005). Neurology. 90(15_supplement). 1 indexed citations
12.
Jankovic, Joseph, Ira Goodman, Beth Safirstein, et al.. (2018). Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease. JAMA Neurology. 75(10). 1206–1206. 224 indexed citations
13.
Olanow, C. Warren, Fabrizio Stocchi, Werner Poewe, et al.. (2018). Efficacy and safety of subcutaneous L-dopa/carbidopa (ND0612H) infusion in fluctuating PD patients (S26.003). Neurology. 90(15_supplement). 1 indexed citations
14.
Tetrud, James W., Paul A. Nausieda, Grace Liang, et al.. (2016). Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. Journal of the Neurological Sciences. 373. 116–123. 4 indexed citations
15.
Hermanowicz, Neal, Aaron Ellenbogen, Gordon Irving, et al.. (2016). The Effect of Gabapentin Enacarbil on Pain Associated with Moderate-to-Severe Primary Restless Legs Syndrome in Adults: Pooled Analyses from Three Randomized Controlled Trials. CNS Drugs. 30(5). 443–454. 5 indexed citations
16.
Ellenbogen, Aaron, Shane Raines, & Stephen Kanes. (2016). Exploratory Trial Results for SAGE-547 in Essential Tremor (P4.297). Neurology. 86(16_supplement). 3 indexed citations
17.
Stocchi, Fabrizio, Ann Hsu, Sarita Khanna, et al.. (2014). Comparison of IPX066 with carbidopa–levodopa plus entacapone in advanced PD patients. Parkinsonism & Related Disorders. 20(12). 1335–1340. 53 indexed citations
18.
Ellenbogen, Aaron, Stephen Thein, David Winslow, et al.. (2011). A 52-Week Study of Gabapentin Enacarbil in Restless Legs Syndrome. Clinical Neuropharmacology. 34(1). 8–16. 39 indexed citations
19.
Walters, Arthur S., William G. Ondo, Clete A. Kushida, et al.. (2009). Gabapentin Enacarbil in Restless Legs Syndrome. Clinical Neuropharmacology. 32(6). 311–320. 58 indexed citations
20.
Addy, Carol, C. Assaid, David Hreniuk, et al.. (2009). Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease. The Journal of Clinical Pharmacology. 49(7). 856–864. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Adjmal Nahimi Breakdown of academic impact, for papers by Tiffany Young Breakdown of academic impact, for papers by Karen Frei Breakdown of academic impact, for papers by Oren Cohen Breakdown of academic impact, for papers by Toni L. Pitcher Breakdown of academic impact, for papers by Michail E. Kalaitzakis Breakdown of academic impact, for papers by Shunnan Ge Breakdown of academic impact, for papers by Sara Pietracupa Breakdown of academic impact, for papers by T. Shibazaki Breakdown of academic impact, for papers by Silvia Eshuis
Rankless by CCL
2026